Author: Newsdesk

NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Marqeta, Inc. (NASDAQ: MQ) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Marqeta, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/marqeta-inc.

Investors have until February 7, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Marqeta securities.   The first-filed case is pending in the U.S. District Court for the Northern District of California and is captioned Wai v. Marqeta, Inc., et al., No. 24-cv-8874.

Why was Marqeta Sued for Securities Fraud?

Marqeta is a financial technology company that provides a card issuing platform, enabling businesses to create and manage customized payment cards. During the relevant period, Marqeta discussed its ability to attract and retain customers while continuing to achieve operational efficiencies given the purported investments it already made into its compliance infrastructure.

In truth, it is alleged that at the time the statements were made, Marqeta experienced longer customer onboarding timelines caused by heightened regulatory scrutiny and insufficient investments into the Company’s compliance apparatus.

The Stock Declines as the Truth is Revealed        

On November 4, 2024, the Company reported its third quarter 2024 financial results and cut its full year 2025 growth outlook, due to “heightened scrutiny of the banking environment and specific customer program changes.” On the earnings call the same day, the Company revealed that “the regulatory scrutiny” had “clearly ratcheted up” in the “first few months of 2024.” Marqeta also admitted that the impact the increased scrutiny had on the Company’s business “became apparent over the last few months.”

This news caused the price of the Company’s stock to fall over 42%, from a closing price of $5.95 per share on November 4, 2024, to $3.42 per share on November 5, 2024.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/marqeta-inc

.

What Can You Do?

If you invested in Marqeta you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/marqeta-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/marqeta-inc

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Zeta Global Holdings Corp. (NYSE: ZETA) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Zeta, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/zeta-global-holdings-corp.

Investors have until January 21, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Zeta securities.   The case is pending in the U.S. District Court for the Southern District of New York and is captioned Davoodi v. Zeta Global Holdings Corp., et al., No. 24-cv-08961.

What is the Lawsuit About?

Zeta is a cloud-based technology company that provides a marketing platform to assist marketers in acquiring customers. The complaint alleges that Zeta represented that its marketing platform was powered by the industry’s largest opted-in data set.

On November 13, 2024, prominent investment research firm Culper Research published a report titled: “Zeta Global Holdings Corp (ZETA): Shams, Scams, and Spam.” Based on Culper’s investigation that included proprietary interviews with industry experts and former Zeta employees, the research firm found that Zeta’s data set had been generated from a network of “consent farms” – i.e., sham websites designed to gather consumer data under false pretenses or awards that did not exist. Culper Research further wrote that these consent farms drove almost the entirety of Zeta’s growth over the past 2+ years, representing 56% of its Adjusted EBITDA, and could result in devastating regulatory action.

The news caused a significant decline in the price of Zeta stock. On November 13, 2024, the price of the company’s stock fell 37%, from a closing price of $28.22 per share on November 12, 2024, to $17.76 per share on November 13, 2024.

Click here for more information:

https://www.bfalaw.com/cases-investigations/zeta-global-holdings-corp

.

What Can You Do?

If you invested in Zeta you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/zeta-global-holdings-corp

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/zeta-global-holdings-corp

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against PACS Group, Inc. (NYSE: PACS) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in PACS, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/pacs-group-inc.

Investors have until January 13, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in PACS securities.   The case is pending in the U.S. District Court for the Southern District of New York and is captioned Manchin v. PACS Group, Inc., et al., No. 24-cv-08636.

What is the PACS Lawsuit About?

The Complaint alleges that PACS is one of the largest operators of skilled nursing facilities in the United States. As alleged, PACS repeatedly represented to shareholders that it possesses a winning “turnaround” strategy to make its nursing facilities profitable. However, in truth, it is alleged that PACS’s turnaround was driven by illicitly accessing Medicare benefits for thousands of patients.

On November 4, 2024, prominent investment research firm Hindenburg Research published a report titled: “PACS Group: How to Become A Billionaire In The Skilled Nursing Industry By Systematically Scamming Taxpayers.” After a 5-month investigation that included interviews with 18 former PACS employees, competitors, and an analysis of more than 900 PACS facility cost reports, Hindenburg alleged that “PACS abused a COVID-era waiver, inappropriately accessing skilled care Medicare benefits for thousands of patients across its national portfolio of facilities.” Hindenburg further estimated that “the scheme drove more than 100% of PACS’ operating and net income from 2020 – 2023, enabling PACS to IPO in early 2024 with the illusion of legitimate growth and profitability.”

On November 6, 2024, PACS then announced that it was postponing its Q3 earnings and that it had “received civil investigative demands from the federal government regarding the Company’s reimbursement and referral practices that may or may not be related to this week’s third-party report.”

The news caused a significant decline in the price of PACS stock. On November 4, 2024, the price of the company’s stock fell 27.8%, from a closing price of $42.94 per share on November 1, 2024, to $31.01 per share on November 4, 2024. On November 6, 2024, the price of the company’s stock fell 38.8%, from a closing price of $29.54 per share on November 5, 2024, to $18.09 per share on November 6, 2024.

Click here if you Suffered Losses:

https://www.bfalaw.com/cases-investigations/pacs-group-inc

.

What Can You Do?

If you invested in PACS you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/pacs-group-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/pacs-group-inc

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) for potential violations of the federal securities laws.

If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

Why is BioAge being Investigated?

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The company’s lead product candidate, azelaprag, is an orally available small-molecule agonist of the apelin receptor (APJ), designed to enhance weight loss.

During the relevant period, the company stated that azelaprag was well-tolerated in 265 individuals across eight Phase 1 clinical trials and that following the company’s IPO it was “well-equipped to advance our clinical programs[.]”

The Stock Declines as the Truth is Revealed

On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. The company stated that the decision to discontinue the STRIDES Phase 2 study of azelaprag “became clear” due to “the emerging safety profile of the current doses tested[.]”

This news caused the price of the company’s stock to decline over 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.

Click here for more information:

https://www.bfalaw.com/cases-investigations/bioage-labs-inc

.

What Can You Do?

If you invested in BioAge you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/bioage-labs-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/bioage-labs-inc

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) —  Leading securities law firm Bleichmar Fonti & Auld LLP announces that that it has filed a class action lawsuit for violations of the federal securities laws against The Toronto-Dominion Bank and certain of the Company’s senior executives.

If you invested in TD Bank, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/the-toronto-dominion-bank.

Investors have until December 23, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in TD Bank securities.   The case is pending in the U.S. District Court for the Southern District of New York and is captioned Gonzalez v. The Toronto-Dominion Bank, No. 24-cv-09445.

What is the Lawsuit About?

TD Bank is the sixth largest bank in North America and tenth largest bank in the U.S. The complaint alleges that during the Class Period, defendants misrepresented TD Bank’s Bank Secrecy Act and anti-money laundering controls, processes, and procedures. And in 2023, when investors started to learn that TD Bank’s regulators were investigating the adequacy of the Company’s AML controls, Defendants repeatedly minimized and downplayed the extent of the problems.

On May 2, 2024, The Wall Street Journal reported that a U.S. Department of Justice (“DOJ”) investigation into the Company’s AML controls focused on “how Chinese crime groups and drug traffickers” used TD Bank to launder money from the sale of fentanyl in the United States and that “[t]he investigation was launched after agents uncovered an operation. . . that laundered hundreds of millions of dollars in proceeds . . . through TD.” This news caused the price of TD Bank stock to decline $3.42 per share, or 5.9%, from $58.08 per share on May 2, 2024, to $54.66 per share on May 3, 2024.

Then, on October 10, 2024, TD Bank disclosed that it entered into consent orders with the Office of the Comptroller of the Currency (“OCC”), the Federal Reserve Board, and the Financial Crimes Enforcement network, as well as plea agreements with DOJ related to its inadequate AML controls. TD Bank revealed that under the terms of the consent orders and plea agreements the Company would, among other requirements, pay $3.09 billion in fines and penalties, and that the OCC had imposed an asset cap on TD Bank that would stifle the Company’s growth. This news caused the price of TD Bank stock to decline $4.07 per share, or 6.4%, from $63.51 per share on October 9, 2024, to $59.44 per share on October 10, 2024.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/the-toronto-dominion-bank

.

What Can You Do?

If you invested in TD Bank you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/the-toronto-dominion-bank

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/the-toronto-dominion-bank

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against ASML Holding N.V. (NASDAQ: ASML) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in ASML, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/asml-holding-nv.

Investors have until January 13, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in ASML securities.   The case is pending in the U.S. District Court for the Southern District of New York and is captioned City of Hollywood Firefighters’ Pension Fund v. ASML Holding N.V., et al., No. 24-cv-8664.

What is the Lawsuit About?

ASML is a leading supplier to the semiconductor industry, providing photolithography machines to chipmakers that are used in the semiconductor fabrication process.

The complaint alleges that ASML repeatedly represented to shareholders that new export controls on semiconductor technology announced by the Dutch government would not have a material effect on ASML’s financial outlook, and that ASML was on a path to recovery in its sales.

On October 15, 2024, ASML announced earnings significantly lower than expectations. The Company attributed this to a market that was “taking longer to recover” and admitted that “[i]t now appears the recovery is more gradual than previously expected.” On this news, the price of the Company’s stock fell 16%, from a closing price of $872.27 per share on October 14, 2024, to $730.43 per share on October 15, 2024.

Then, during the accompanying earnings call with investors on October 16, 2024, the Company attributed the poor earnings results to “a reflection of the slow recovery in the traditional [semiconductor] end markets as customers remain cautious in the current environment.” The Company also disclosed that the decline in ASML’s sales to China would also negatively impact the Company’s gross margins. On this news, the price of the Company’s stock fell 6.4%, from a closing price of $730.43 per share on October 15, 2024, to $683.52 per share on October 16, 2024.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/asml-holding-nv

.

What Can You Do?

If you invested in ASML you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/asml-holding-nv

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/asml-holding-nv

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) —  Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Symbotic Inc. (NASDAQ: SYM) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Symbotic, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/symbotic-inc.

Investors have until February 3, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Symbotic securities. The case is pending in the U.S. District Court for the District of Massachusetts and is captioned Decker v. Symbotic Inc., et al., No. 24-cv-12976.

What is the Symbotic Class Action Lawsuit About?

Symbotic Inc. develops and operates robotics systems to automate and optimize warehouse and supply chain operations for major retailers and distributors. During the relevant period, the company represented that its financial statements were accurate and that its internal controls over financial reporting were effective.

In contrast with these representations, on November 27, 2024, Symbotic announced a delay in filing its Form 10-K for its fiscal year 2024 due to identified errors in revenue recognition and announced material weaknesses in its internal controls over financial reporting.  Symbotic revealed that it discovered issues related to premature expense recognition and unbillable cost overruns, which affected system revenue recognition in multiple quarters of its fiscal year 2024.  The company estimated a $30–$40 million reduction in system revenue, gross profit, and adjusted EBITDA for its fiscal year 2024 and reduced its revenue outlook for the first quarter of fiscal 2025 to $480–$500 million, from $495–$515 million, and adjusted EBITDA of $12–16 million, from $27–$31 million. 

This news caused the price of the company’s stock to decline over 35% during the course of trading on November 27, 2024.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/symbotic-inc

.

What Can You Do?

If you invested in Symbotic you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/symbotic-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/symbotic-inc

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a lawsuit against Acadia Healthcare Company, Inc. (NASDAQ: ACHC) and certain of the Company’s senior executives.

If you invested in Acadia Healthcare, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/acadia-healthcare-company-inc.

Investors have until December 16, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Acadia Healthcare’s securities.   The case is pending in the U.S. District Court for the Middle District of Tennessee and is captioned Dyar v. Acadia Healthcare Company, Inc., No. 3:24-cv-01300. The lawsuit can be found here: https://www.bfalaw.com/siteFiles/Cases/Acadia_Dyar_Complaint.pdf

What is the Lawsuit About?

Acadia is one of the largest for-profit chains of psychiatric hospitals in the United States. The complaint alleges that during the relevant period, the Company misrepresented that its financial results were driven by insurance fraud and holding vulnerable people against their will in its facilities, including in cases where it was not medically necessary to do so.

On September 1, 2024, the New York Times published an article titled “How a Leading Chain of Psychiatric Hospitals Traps Patients.” The New York Times’s “investigation found that some of that success was built on a disturbing practice: Acadia has lured patients into its facilities and held them against their will, even when detaining them was not medically necessary.” On this news, the price of Acadia stock fell $3.72 per share, or 4.5%, to close at $78.21 per share on September 3, 2024.

On September 27, 2024, Acadia disclosed that it received a request for information from the U.S. Attorney’s Office for the Southern District of New York, a grand jury subpoena from the U.S. District Court for the Western District of Missouri, and that it expects similar requests from the U.S. Securities and Exchange Commission related to the Company’s patient admissions, as well as its length of stay and billing practices.  This news caused a significant 16% decline in the price of Acadia stock, from $75.66 per share on September 26, 2024 to $63.28 per share on September 27, 2024.

Then, on October 18, 2024, the New York Times published an article titled “Veterans Dept. Investigating Acadia Healthcare for Insurance Fraud,” stating that the Veterans Affairs Department is investigating whether Acadia is defrauding government health insurance programs by holding patients longer than is medically necessary. The New York Times also stated that several former Acadia employees in Georgia and Missouri have also been interviewed by agents from the F.B.I. and the inspector general’s office of the Health and Human Services Department. This news caused a significant 12% decline in the price of Acadia stock, from $59.32 per share on October 17, 2024 to $52.03 per share on October 18, 2024.

Click here for more information:

https://www.bfalaw.com/cases-investigations/acadia-healthcare-company-inc

.

What Can You Do?

If you invested in Acadia Healthcare you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/acadia-healthcare-company-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/acadia-healthcare-company-inc

Attorney advertising. Past results do not guarantee future outcomes.